Navigation Links
Actos Lawsuit News: Bernstein Liebhard LLP Notes Scheduling of Next Status Conference in Federal Actos Bladder Cancer Litigation
Date:9/14/2013

der cancer last year, alleges that Takeda knew as early as 2005 that research had linked prolonged use of the drug to the disease cancer, but waited six years to issue a public warning. The complaint further alleges that the company’s conduct was motivated by a desire to increase Actos sales. (An v. Nieberlein, 24-C12003565, Circuit Court for the City of Baltimore, State of Maryland.)

The first trial involving Actos and bladder cancer concluded this past April in Los Angeles Superior court, with that jury awarding more than $6 million to a man who was diagnosed with bladder cancer after taking Actos for four years. However, court documents indicate that the judge overseeing the case granted Takeda Pharmaceuticals’ request to set aside the verdict. (Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535, California Superior Court)

The litigation involving Actos bladder cancer claims began to move forward in June 2011, after the U.S. Food & Drug Administration (FDA) warned that use of Actos for one year could increase a patient’s risk for the disorder. At that time, the FDA mandated that new information about the association between Actos and bladder cancer be added to the drug’s label.

Patients who took Actos for an extended period of time and later developed bladder cancer may be entitled to compensation for medical expenses, lost wages, pain and suffering, and more. Learn More about filing an Actos lawsuit by visiting Bernstein Liebhard LLP’s website. For additional information, please contact Bernstein Liebhard LLP today by calling 800-511-5092.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based la
'/>"/>

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related medicine news :

1. After Taking Diabetes Drug Actos for Nearly Seven Years, Florida Man Developed Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP
2. Actos Lawsuit Filed By Wright & Schulte on Behalf of Ohio Man Alleges Extended Use of Type-2 Diabetes Drug Caused Him to Develop Bladder Cancer
3. Actos Bladder Cancer Lawsuits Move Forward, with Issuance of New Order in Federal Actos Litigation, Bernstein Liebhard LLP Reports
4. Lawsuit Alleges Takeda Pharmaceutical Co., Maker of Diabetes Drug Actos, Didn’t Warn of the Drug’s Risks Soon Enough; Parker Waichman LLP Responds
5. Actos Lawsuit News: Bernstein Liebhard LLP Notes Start of Second Actos Bladder Cancer Trial in Maryland State Court
6. Actos Bladder Cancer Lawsuits Help: Resource4thePeople Reports Number of Consolidated Federal Cases Climbs to over 2,500
7. Actos Lawsuits Move Forward Following Latest Status Conference in Federal Actos Bladder Cancer Litigation
8. Oregon Man Developed Bladder Cancer Brought on by Years of Ingesting Diabetes Drug Actos, Alleges Lawsuit Filed by Parker Waichman LLP
9. Florida Woman Developed Bladder Cancer After Taking Actos to Treat her Type II Diabetes, Alleges Lawsuit Filed by Parker Waichman LLP
10. Years of Ingesting Diabetes Drug Actos Caused Florida Man to Develop Bladder Cancer, Alleges Lawsuit Filed by Parker Waichman LLP
11. Actos Lawsuits Alleging Bladder Cancer Update: Resource4thePeople Reports Judge Continues to Move Multidistrict Litigation Forward
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... The Restore My Blood Sugar review recently published ... levels can now find an amazingly successful method of reducing ... created by D. Chao and Andrew Forester who claim that ... it comes to normalizing blood sugar levels. Chao actually is ... to the cure of diabetes that all patients should find ...
(Date:7/30/2014)... July 30, 2014 New changes are in ... plans to move to a new facility. The official date ... will be moving soon. , MedX Pharmacy will be moving ... Pearland, TX 77581. This is the old Wells Fargo building. ... and will include a drive thru for convenient drop-off and ...
(Date:7/30/2014)... Conducting Advanced Root Cause Analysis ... and Innovative Techniques to Improve the Quality of ... Sept. 17-18, 2014 – Raleigh, NC, http://www.fdanews.com/CAPAWorkshopRaleigh ... for 483 observations since 1997. , The FDA's ... CAPA program has never been more important. , ...
(Date:7/30/2014)... drug to treat malaria, is now widespread throughout ... ( P. falciparum ) parasites that cause the ... mutation in the parasites. However, a six-day course ... three-day coursehas proved highly effective in treating drug-resistant ... the New England Journal of Medicine . ...
(Date:7/30/2014)... July 30, 2014 (HealthDay News) -- It can happen in ... television, dresser or computer monitor and gets critically injured when ... a young child should look around their homes and imagine ... child. Imagining it is better than it becoming a reality," ... Physicians, said in a college news release. Between 2009 ...
Breaking Medicine News(10 mins):Health News:Restore My Blood Sugar Review Reveals Exclusive Ways to Normalize Blood Sugar 2Health News:MedX Pharmacy Relocates to New Facility 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 2Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 3Health News:FDAnews Workshop: Conducting Advanced Root Cause Analysis CAPA Investigations, Sept. 17-18, 2014, Raleigh, NC 4Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News:Tip-Over Furniture Can Kill Kids 2
... WASHINGTON and DUBLIN , March ... Ireland -based, physician-led global certification company, today announced that ... Mark on its new LuV300 vacuum with Kompressor® technology. ... range of products from worldwide manufacturers to determine their ...
... ... , ... ... On Thursday, March 18 , lawyers from the U.S. Department of Justice will appear in Federal District ...
... Care to Pay for It Makes Little Sense , ... ... PRINCETON, N.J. , March 16 Statement ... , , ...
... and suffering caused by antibiotic-resistant bacterial infections continue to rise ... (IDSA) is urging a global commitment to develop 10 new ... to address this public health crisis and safeguard patients, health. ... a statementpublished in the April 15 issue of Clinical ...
... has long been identified as a risk factor for cardiovascular ... researchers at the University of Rochester Medical Center found that ... risk of dying suddenly from cardiac causes. Scientists found ... underweight patients had a 76 percent increase in risk ...
... ... a new laundry detergent for U.S. consumers concerned about their budget as well as ... contains 10 ounces of macro-molecule laundry detergent which cleans for up to 12 months ... over 200 washes. , ...
Cached Medicine News:Health News:Ireland's Allergy Standards Limited Adds LG Electronics to Host of Companies Making Allergy-Certified Consumer Products 2Health News:Ireland's Allergy Standards Limited Adds LG Electronics to Host of Companies Making Allergy-Certified Consumer Products 3Health News:Ireland's Allergy Standards Limited Adds LG Electronics to Host of Companies Making Allergy-Certified Consumer Products 4Health News:Ireland's Allergy Standards Limited Adds LG Electronics to Host of Companies Making Allergy-Certified Consumer Products 5Health News:Court Hearing Thursday on Physicians' Challenge to 'Obamacare': Doctors Argue Against 'Arbitrary Power and Tyranny' 2Health News:Court Hearing Thursday on Physicians' Challenge to 'Obamacare': Doctors Argue Against 'Arbitrary Power and Tyranny' 3Health News:Court Hearing Thursday on Physicians' Challenge to 'Obamacare': Doctors Argue Against 'Arbitrary Power and Tyranny' 4Health News:NJHA: Charity Care Must Be a Priority as Uninsured Burden Grows 2Health News:ID physicians call for 10 new antibiotics by 2020 2Health News:As girth grows, risk of sudden cardiac death shrinks 2Health News:As girth grows, risk of sudden cardiac death shrinks 3Health News:Oransi Launches Robby Wash High Efficiency Laundry Detergent in U.S. – 10 Ounces Replaces 75 lbs. of Traditional Laundry Detergent 2Health News:Oransi Launches Robby Wash High Efficiency Laundry Detergent in U.S. – 10 Ounces Replaces 75 lbs. of Traditional Laundry Detergent 3
(Date:7/30/2014)... 30, 2014  InnoPharma, Inc. today announced the first ... equivalent of Zyprexa® injection), in Canada.  Olanzapine is indicated ... in patients with schizophrenia or bipolar I mania. ... InnoPharma has entered into an agreement with Sandoz Canada ... make, use, sell, market and distribute Olanzapine Injection in ...
(Date:7/30/2014)... and PARIS , July 30, ... ) and Sanofi (EURONEXT: SAN and NYSE: ... ODYSSEY trials of alirocumab in people with hypercholesterolemia met ... from baseline in low-density lipoprotein cholesterol (LDL-C) at 24 ... an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin ...
(Date:7/30/2014)... and NEW YORK , July ... a developer of new products for oncology supportive care, ... ® , has been featured in an article on ... Symptoms in Head and Neck Cancers."  Dr. Steve ... insight on the growing demand seen in the oncology ...
Breaking Medicine Technology:InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 2Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 3Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 4Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 5Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 6Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 7Regeneron and Sanofi Report Positive Top-Line Results from Nine Phase 3 Trials of Alirocumab in People with Hypercholesterolemia 8Access Pharmaceuticals Featured On OncLive.com 2Access Pharmaceuticals Featured On OncLive.com 3
... Perrigo Company (Nasdaq: PRGO;TASE) today announced that Perrigo Executive Vice President and ... Sachs Global Healthcare Conference on Tuesday, June 15 , at ... Los Angeles .  The presentation will be webcast on the following ... , ...
... Epocal, Inc., a leading edge provider of point ... Food and Drug Administration (FDA) clearance to market its new ... from the epoc System are used to evaluate acid-base status ... acidity of the blood).  The addition of lactate to the ...
Cached Medicine Technology:Epocal Announces FDA Clearance of Lactate Test 2
Ideal for chemical processing that requires downward flow of exhaust fumes. Powderful 1200 CFM blower draws fumes into sub-surface bonded charcoal filter for safe removal of organic vapors (final HEP...
... benchtop fume hood ventilates and ... indoor release of exhaust. Bonded ... contaminants. Configurations are available with ... include final HEPA filter, work ...
... proof polypropylene exhaust hoods are designed to ... and draw a stream of air across ... the operator. Other sizes and types of ... double-slot are available on special order in ...
... Benchtop Fume Hood is an economical unit ... which a number of fume hoods are ... colleges and universities. Features include a one-piece ... rounded inside corners for easy cleaning. A ...
Medicine Products: